Jardiance Cost in Illinois 2026: Prices, Insurance, Medicaid, and Compounded Options

What Is the Retail Price of Jardiance in Illinois in 2026?

The manufacturer list price for Jardiance is approximately $680 per month in 2026 at Illinois retail pharmacies, covering either the 10 mg or 25 mg tablet in a 30-count supply. Without insurance or a savings program, most patients pay close to that figure at chains like Walgreens, CVS, and Jewel-Osco pharmacies across Chicago and downstate Illinois. GoodRx and similar discount platforms sometimes reduce cash-pay prices to the $550 to $640 range depending on the ZIP code, but savings vary week to week and by pharmacy contract.

Jardiance is manufactured by Boehringer Ingelheim and co-marketed by Eli Lilly. The FDA approved empagliflozin in August 2014 for type 2 diabetes mellitus and subsequently for heart failure with reduced ejection fraction (HFrEF), heart failure with preserved ejection fraction (HFpEF), and chronic kidney disease (CKD). Those expanded indications mean more Illinois patients are now clinically eligible for the drug, which in turn influences insurer and Medicaid coverage decisions. [1, 2]

No FDA-approved generic empagliflozin existed as of early 2026. Patent exclusivity protections and ongoing Hatch-Waxman litigation mean branded Jardiance retains exclusivity, keeping the list price high. The absence of a generic is the primary driver of cost burden for uninsured or underinsured Illinois patients. [3]

For reference, the 2024 IQVIA Institute report on medicine spending in the U.S. found that SGLT2 inhibitors as a class ranked among the top 10 drug classes by total net spending, reflecting both volume growth and sustained list prices. [4]

Does Illinois Medicaid Cover Jardiance?

Illinois Medicaid (Medicaid Managed Care and FFS) covers Jardiance with prior authorization (PA) for adult members with type 2 diabetes, heart failure, or CKD who meet clinical criteria. Approval is not automatic, and the PA process requires documented diagnosis codes, evidence of a prescriber attempt at first-line agents where clinically appropriate, and in some managed care plans, a letter of medical necessity from the treating provider.

The Illinois Department of Healthcare and Family Services (IHFS) Preferred Drug List (PDL) classifies Jardiance as a covered non-preferred drug, meaning the PA hurdle exists but the drug is not excluded. Patients enrolled in one of Illinois's Medicaid managed care organizations (MCOs), including Meridian Health Plan, Molina Healthcare of Illinois, or Blue Cross Community Health Plans, face MCO-specific PA criteria that may differ slightly from the state FFS criteria. Providers should verify the specific MCO's PA form before submitting. [5]

Once PA is approved, Illinois Medicaid members typically pay a nominal copay of $3 to $4 per fill for brand drugs, making Medicaid arguably the most cost-effective access pathway for eligible low-income Illinois residents. Income eligibility for Illinois Medicaid (All Kids, FamilyCare, ACA expansion) uses 138% of the federal poverty level as the main threshold for adult coverage. [6]

The American Diabetes Association 2025 Standards of Care state: "In adults with type 2 diabetes and established cardiovascular disease, an SGLT2 inhibitor with demonstrated cardiovascular benefit is recommended to reduce the risk of major adverse cardiovascular events." [7] That guideline language supports PA approval for patients who meet the cardiovascular indication.

Is Compounded Empagliflozin Legal in Illinois?

Compounded empagliflozin is legally available in Illinois through state-licensed 503A compounding pharmacies operating under the federal Drug Quality and Security Act and Illinois Pharmacy Practice Act. A 503A pharmacy compounds drug products for individual patients based on a valid prescription from a licensed prescriber. Illinois has no state-level ban on compounding SGLT2 inhibitors, so patients with a prescription from an Illinois-licensed provider can receive compounded empagliflozin from a 503A facility.

The key legal distinction is between 503A pharmacies (patient-specific, prescription-required) and 503B outsourcing facilities (bulk compounding, FDA-registered). Compounded empagliflozin is not on the FDA's 503B drug shortage list as of 2025, which means 503B bulk compounding for office use is on less firm regulatory ground. Patients obtaining compounded empagliflozin should confirm the dispensing pharmacy holds an active Illinois Board of Pharmacy 503A license and that a valid, individualized prescription is on file. [8]

Cost is the main reason patients consider compounding. Some Illinois 503A pharmacies price compounded empagliflozin capsules well below the $680/month brand list price, though exact pricing depends on the formulation, dose, and individual pharmacy. Patients should ask for a Certificate of Analysis (CoA) confirming potency, purity, and sterility testing before accepting any compounded product.

The FDA has not approved any compounded empagliflozin product for safety and efficacy; compounded drugs bypass FDA's standard review process. That distinction matters clinically. The EMPA-REG OUTCOME trial that demonstrated a 38% relative risk reduction in cardiovascular death used the FDA-approved Jardiance formulation, not a compound. [9]

How Does Private Insurance Cover Jardiance in Illinois?

Most major commercial insurers operating in Illinois place Jardiance on Tier 3 (preferred brand) or Tier 4 (non-preferred brand) of their formularies, resulting in patient cost shares ranging from roughly $45 to $120 per 30-day supply after deductible. Exact cost depends on the specific plan, benefit year, and whether the patient has met their annual deductible.

Illinois residents covered through ACA marketplace plans, employer-sponsored insurance, or individual PPO/HMO plans will generally find Jardiance covered, but the tier placement varies. Blue Cross Blue Shield of Illinois, Aetna, Cigna, Humana, and United Healthcare all have IL-specific formularies updated annually in October for the following benefit year. Patients should check their plan's 2026 formulary drug list, available on each insurer's member portal, to confirm current tier placement before the plan year begins. [10]

The Consolidated Appropriations Act of 2021 required insurers covering preventive services without cost-sharing to include USPSTF A/B-rated preventive drugs. Type 2 diabetes prevention medications and CKD-protective agents are increasingly cited in guideline updates that may shift formulary tier politics over time, though Jardiance itself is not yet classified as a purely preventive drug for cost-sharing purposes. [11]

Patients with Medicare Part D coverage should note that the Inflation Reduction Act (IRA) caps out-of-pocket drug spending at $2,000 per year starting in 2025 for Part D enrollees. For Illinois Medicare beneficiaries who previously spent more than $2,000 annually on Jardiance, this cap represents meaningful relief. [12]

How Does the Boehringer Ingelheim / Lilly Savings Card Work in Illinois?

The Jardiance Savings Card, offered jointly by Boehringer Ingelheim and Eli Lilly, allows commercially insured patients in Illinois to pay as low as $10 per month for a 30-day supply, with a maximum benefit of up to $150 per fill (terms as of 2025). Illinois patients enroll at the official Jardiance savings card program page and present the card at any participating pharmacy.

Eligibility restrictions apply. The savings card is not valid for patients enrolled in any federal or state government insurance program, including Medicare, Medicaid, TRICARE, or the Veterans Affairs health system. Uninsured patients are also ineligible for the commercial card but may qualify for Boehringer Ingelheim's patient assistance program (PAP), which provides Jardiance at no cost to patients who meet income criteria (generally at or below 400% of the federal poverty level). [13]

Illinois patients without insurance who do not qualify for the PAP should compare GoodRx, RxSaver, and pharmacy-specific discount programs. Mark Cuban's Cost Plus Drugs does not currently list empagliflozin, given the lack of a generic, but the platform is worth checking periodically as patent situations evolve.

What Clinical Evidence Supports Empagliflozin's Use?

Empagliflozin's cost discussion is inseparable from its clinical profile. The EMPA-REG OUTCOME trial (N=7,020), published in the New England Journal of Medicine in 2015, randomized adults with type 2 diabetes and established cardiovascular disease to empagliflozin 10 mg or 25 mg versus placebo. The primary outcome (3-point MACE: CV death, nonfatal MI, nonfatal stroke) occurred in 10.5% of the empagliflozin group versus 12.1% of placebo (HR 0.86; 95% CI 0.74 to 0.99; P<0.001 for non-inferiority, P=0.04 for superiority). CV death was reduced by 38% (HR 0.62; 95% CI 0.49 to 0.77; P<0.001). [9]

The EMPEROR-Reduced trial (N=3,730), published in NEJM in 2020, showed empagliflozin reduced the composite of CV death or hospitalization for heart failure by 25% (HR 0.75; 95% CI 0.65 to 0.86; P<0.001) in patients with HFrEF, regardless of diabetes status. [14]

EMPEROR-Preserved (N=5,988), also published in NEJM in 2021, extended the heart failure benefit to patients with HFpEF (LVEF above 40%), with a 21% relative risk reduction in the primary composite (HR 0.79; 95% CI 0.69 to 0.90; P<0.001). [15]

For CKD, the EMPA-KIDNEY trial (N=6,609) published in NEJM Evidence in 2023 showed empagliflozin 10 mg reduced the composite of kidney disease progression or CV death by 28% (HR 0.72; 95% CI 0.64 to 0.82; P<0.001) compared with placebo across a broad range of CKD eGFR levels, including patients with eGFR as low as 20 mL/min/1.73m². [16]

These trial results directly inform Illinois Medicaid PA criteria and insurer coverage decisions. A provider citing EMPA-KIDNEY outcomes for a CKD patient's PA letter has strong published data to support the request.

Can I Get a Jardiance Prescription via Telehealth in Illinois?

Telehealth prescribing of Jardiance is permitted in Illinois for both new and established patients. Illinois enacted permanent telehealth parity legislation following the COVID-19 public health emergency, meaning licensed Illinois physicians, nurse practitioners, and physician assistants can evaluate patients remotely and prescribe empagliflozin when clinically appropriate, without requiring a prior in-person visit. [17]

Illinois-licensed telehealth providers must conduct a synchronous audio-visual evaluation (not audio-only for prescribing controlled substances, though empagliflozin is not a controlled substance). The prescriber must document a valid patient-provider relationship, obtain a medication history, and confirm appropriate diagnosis. Standard of care applies regardless of whether the visit is in-person or virtual.

HealthRX and similar telehealth platforms operating in Illinois can therefore prescribe Jardiance or refer patients for compounded empagliflozin from a licensed 503A pharmacy, subject to a clinical evaluation. Patients should verify the platform's prescribers hold active Illinois licenses via the Illinois Department of Financial and Professional Regulation (IDFPR) license lookup.

What Is the Cheapest Way to Get Jardiance in Illinois in 2026?

The lowest-cost legal pathways for Illinois patients fall into three broad tiers depending on insurance status.

Illinois Medicaid-eligible patients pay roughly $3 to $4 per fill after a successful PA approval. This is the most affordable route for patients who qualify by income and diagnosis.

Commercially insured patients using the Boehringer Ingelheim/Lilly savings card pay as low as $10 per month, capped at $150 per fill. This card effectively eliminates most out-of-pocket cost for patients whose plans cover Jardiance on any tier.

Uninsured or underinsured patients face the steepest challenge. Options in order of typical cost include: (1) Boehringer Ingelheim PAP (free for eligible patients), (2) compounded empagliflozin from a licensed Illinois 503A pharmacy (pricing varies; ask for a CoA), (3) GoodRx or similar discount cards at retail pharmacies (may reduce cash price to the $550 to $640 range), and (4) full cash pay at list price ($680/month). [13]

The NEJM Catalyst 2023 analysis of SGLT2 inhibitor cost-effectiveness found that at list price, empagliflozin exceeded standard willingness-to-pay thresholds for some lower-risk patients, but remained cost-effective for high-cardiovascular-risk and CKD populations at discounted or rebated net prices. [18] That framing matters for understanding why Illinois Medicaid restricts coverage to higher-risk patients via PA rather than covering all type 2 diabetics without restriction.

Illinois-Specific Prescriber and Pharmacy Considerations

Illinois imposes no additional state-level restrictions on empagliflozin prescribing beyond federal FDA labeling. Any Illinois-licensed MD, DO, NP (with prescriptive authority), or PA (with supervising agreement where required) can prescribe Jardiance. Illinois granted full practice authority to advanced practice registered nurses (APRNs) in 2018 under PA 100-0513, meaning NPs practicing in telehealth or primary care clinics can prescribe empagliflozin independently. [17]

For patients picking up at retail in Illinois, 90-day supplies are available through most major pharmacy chains and mail-order arms of PBMs (Express Scripts, CVS Caremark, OptumRx). A 90-day fill typically saves patients one copay tier compared with three separate 30-day fills, though this depends on plan benefit design.

Illinois pharmacies dispensing any compounded drug must post their 503A license conspicuously and provide patients with written information about the compounded nature of the product per 225 ILCS 85/9 (Illinois Pharmacy Practice Act). Patients have the right to request the pharmacy's most recent compounding inspection report from the Illinois Board of Pharmacy. [8]

The FDA drug label for Jardiance contraindicates use in patients with eGFR <20 mL/min/1.73m² for glycemic control (though the CKD indication from EMPA-KIDNEY data updated some labeling language), in patients with type 1 diabetes (risk of DKA), and in patients who are pregnant or breastfeeding. [1] Illinois telehealth and in-person prescribers are expected to screen for these contraindications before prescribing.

Side Effects Illinois Patients and Prescribers Should Know

Empagliflozin carries a class-wide FDA boxed warning regarding the risk of lower-limb amputations (seen most notably with canagliflozin in the CANVAS trial, less so with empagliflozin in EMPA-REG, but the class label carries the warning). Prescribers and patients in Illinois should be aware of the following adverse effects documented in the FDA label and trial data. [1]

Genital mycotic infections occurred in 6.4% of women and 3.1% of men on empagliflozin versus 1.8% and 0.6% respectively for placebo in pooled data from registration trials. Urinary tract infections were also more common, though the absolute risk difference was small. Diabetic ketoacidosis (DKA), including euglycemic DKA (glucose <250 mg/dL), is a rare but serious risk; patients should hold empagliflozin 3 days before major surgery or prolonged fasting per FDA guidance. [1, 2]

Volume depletion and hypotension may occur, particularly in older adults or those on loop diuretics. The EMPEROR-Reduced trial data showed the drug was generally well tolerated in patients with HFrEF, with no excess risk of hypotension-related serious adverse events versus placebo. [14]

Fournier's gangrene (necrotizing fasciitis of the perineum) is a rare but serious adverse event associated with SGLT2 inhibitors as a class. The FDA issued a Drug Safety Communication in 2018 describing 12 cases identified in 5 years across all SGLT2 inhibitors; patients and Illinois prescribers should treat any perineal pain, erythema, or swelling as urgent. [19]